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Abstract 
Background: During COVID‑19 pandemic, elective invasive cardiac procedures (ICP) have been frequently cancelled 
or postponed. Consequences may be more evident in patients with diabetes.
Objectives: The objective was to identify the peculiarities of patients with DM among those in whom ICP were 
cancelled or postponed due to the COVID‑19 pandemic, as well as to identify subgroups in which the influence of DM 
has higher impact on the clinical outcome.
Methods: We included 2,158 patients in whom an elective ICP was cancelled or postponed during COVID‑19 pan‑
demic in 37 hospitals in Spain. Among them, 700 (32.4%) were diabetics. Patients with and without diabetes were 
compared.
Results: Patients with diabetes were older and had a higher prevalence of other cardiovascular risk factors, previous 
cardiovascular history and co‑morbidities. Diabetics had a higher mortality (3.0% vs. 1.0%; p = 0.001) and cardiovas‑
cular mortality (1.9% vs. 0.4%; p = 0.001). Differences were especially important in patients with valvular heart disease 
(mortality 6.9% vs 1.7% [p < 0.001] and cardiovascular mortality 4.9% vs 0.9% [p = 0.002] in patients with and without 
diabetes, respectively). In the multivariable analysis, diabetes remained as an independent risk factor both for overall 
and cardiovascular mortality. No significant interaction was found with other clinical variables.
Conclusion: Among patients in whom an elective invasive cardiac procedure is cancelled or postponed during 
COVID‑19 pandemic, mortality and cardiovascular mortality is higher in patients with diabetes, irrespectively on other 
clinical conditions. These procedures should not be cancelled in patients with diabetes.
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Introduction
The ongoing COVID-19 pandemic, caused by the severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was declared by the World Health Organization (WHO) 
in March 2020 [1]. By January 2021, almost 100 million 
people had suffered the disease, and nearly 2 million have 
died worldwide. Apart from these direct consequences, 
health care systems have been severely overwhelmed, 
negatively impacting on the management of other 
patients that usually require prompt treatment, especially 
those with cardiovascular diseases [2–8]. Specifically, 
invasive cardiac procedures (ICP) have been cancelled or 
postponed in many centers, and this may have fatal con-
sequences for some patients, as we have recently shown 
in a multicenter study from Spain [9].
Cardiovascular diseases constitute the main cause 
of death in patients with diabetes mellitus (DM) [10], 
and among patients with cardiovascular diseases, those 
with DM are at an especially high risk of death [11, 12]. 
Because of that, waiting list in patients pending on car-
diovascular procedures that have been postponed due to 
the pandemic may have especial impact among diabetics 
[9].
The objective was to identify the peculiarities of 
patients with DM among those in whom ICP were can-
celled or postponed due to the COVID-19 pandemic, as 
well as to identify subgroups in which the influence of 
DM has higher impact on the clinical outcome.
Methods
Study population
We have previously published the outcome of patients in 
whom elective ICP were cancelled or postponed when 
the state of alarm due to the COVID-19 pandemic was 
declared in Spain on the 14th of March 2020. In this 
study, 2,158 patients were included in 37 hospitals [8].
At the time of the publication of that study, DM status 
was known in 2,110, whereas no information was availa-
ble for 48 patients. For the present sub-study, doing addi-
tional efforts, directly contacting with the patient or 
obtaining documents from the referral centers, we could 
obtain DM status for all 2158 patients.
Data collection and follow‑up
Data were entered in an electronic database (pInvestiga, 
Moaña, Pontevedra, Spain). Clinical variables, such as 
main cardiovascular disease pending on treatment, type 
of procedure pending to be performed, clinical situation, 
and cardiovascular risk factors, were collected.
Patients were followed-up until the 30th of April 2020 
(45  days) [8]. Patients with DM were compared with 
those without DM, regarding type of pending procedure, 
main cardiovascular disease, functional class for heart 
failure and angina, and other clinical variables. The influ-
ence of DM in different patient subgroups was evaluated.
Definitions
Coronary angiography and/or PCI as the type of pend-
ing procedure included coronary angiography in patients 
with previously diagnosed or suspected CAD, and those 
with previously known CAD pending on PCI (e.g. stage 
procedures). Coronary angiography to rule out CAD as 
the underlying cause of left ventricular dysfunction was 
also included in this category. However, coronary angi-
ography as part of the study of patients pending on any 
type of surgical intervention was included in a different 
category, because the main underlying condition was 
considered to be the disorder pending to be treated (e.g. 
valvular heart disease) rather than the eventual bystander 
of coronary artery disease. Other procedures included 
transcatheter aortic valve implantation (TAVI), percuta-
neous mitral valve repair, left atrial appendage closure, 
percutaneous closure of ASD, or treatment of tricuspid 
regurgitation.
Statistical analysis
Continuous variables are presented as mean ± stand-
ard deviation and compared using the Student t-test or 
appropriate non-parametric tests. Discrete variables 
are presented as percentages (proportions), and com-
pared with the Chi-square test, using Fisher correction 
when needed. Statistical analysis was done using the 
SPSS statistical package (Chicago, Illinois). Associations 
were considered statistically significant when p < 0.05, 
although all p values are presented. Univariable and mul-
tivariable analysis were conducted in order to identify 




Out of the 2,158 patients, 700 (32.4%) were DM. Figure 1 
shows the type of pending procedure in patients with and 
without DM. Coronary diagnostic and/or therapeutic 
intervention was the most frequent pending procedure 
for both groups of patients, but it was more frequent 
in DM than in non-DM (61.5% vs. 49.5%, respectively; 
p < 0.001). The second type of procedure was percutane-
ous valvular intervention, that accounted for 17.9% and 
16.2% for DM and non-DM, respectively (p = 0.300). 
Other diagnostic procedure was pending in 14.2% 
and 25.2% of DM and non-DM patients, respectively 
(p < 0.001). Other therapeutic procedure was pending in 
6.7% and 9.1% in patients with and without DM, respec-
tively (p = 0.060).
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Comparison of patients with and without DM
Table  1 shows the differences among patients with and 
without DM in relation  with clinical characteristics. 
Patients with DM were older, and had a higher prevalence 
of hypertension, hypercholesterolemia, chronic renal fail-
ure, peripheral artery disease, and previously diagnosed 
coronary artery disease including previous infarction, 
and previous myocardial revascularization. Left ventricu-
lar dysfunction was more frequently present in patients 
with DM. Functional class for heart failure (NYHA) was 
similar for patients with and without DM, but functional 
class for angina (CCS) was worse in patients with DM.
Among the 2,158 patients, 559 had previously docu-
mented coronary artery disease. Patients with DM had 
higher frequency of multi-vessel disease (72.9% vs. 
56.7% in non-DM, p < 0.001). Left main disease was also 
more frequent in patients with DM, but differences were 
not statistically significant (13.9% vs. 9.8% in non-DM, 
p = 0.133).
Influence of DM on clinical outcomes
During the 45-day follow-up period, 36 patients died 
(1.7%), most of them due to cardiovascular causes 
(n = 19, 59.4%). Patients with DM had a higher rate 
of both overall mortality (3.0% vs. 1.0% in non-DM, 
p = 0.001) and cardiovascular mortality (1.9% vs. 0.4% in 
non-DM, p = 0.001), whereas differences in non-cardio-
vascular mortality were not statistically different (1.1% vs. 
0.6% in DM and non-DM, respectively; p = 0.196).
Fig. 1 Type of pending procedures in patiens with and without DM
Table 1 Clinical characteristics of patients with and without DM
CAD coronary artery disease, PCI Percutaneous coronary intervention, CABG 
Coronary artery bypass grafting, NYHA New York Heart Association, CCS 
Cardiology Canadian Society
DM
Yes (n = 700) No (n = 1458) P value
Age 72.3 ± 10.0 69.2 ± 12.7  < 0.001
Age ≥ 80 (%) 24.9 21.4 0.078
Female gender (%) 34.9 39.9 0.066
Hypertension (%) 82.9 59.8  < 0.001
Hypercholesterolemia (%) 71.0 47.9  < 0.001
Smoking (%) 30.8 29.3 0.483
Chronic renal failure (%) 13.2 7.5  < 0.001
Peripheral artery disease (%) 14.2 9.0  < 0.001
Previous CAD (%) 41.7 27.4  < 0.001
Previous infarction (%) 17.9 11.4  < 0.001
Previous PCI (%) 23.6 15.5  < 0.001
Previous CABG (%) 6.7 3.4 0.001
Previous valve replacement (%) 3.5 4.9 0.144
Left ventricular dysfunction (%) 27.1 21.4 0.033
NYHA > II (%) 20.1 19.0 0.282
CCS > II (%) 10.0 8.4 0.001
Main cardiovascular condition (%)
 Ischemic heart disease 57.6 47.0  < 0.001
 Valvular heart disease 29.2 36.9
 Other 13.3 16.2
Page 4 of 10Moreno et al. Cardiovasc Diabetol           (2021) 20:69 
In the multivariable analysis, DM remained as an 
independent risk factor both for overall and cardiovas-
cular mortality (Fig. 2).
The proportion of patients that underwent an urgent 
procedure due to clinical instabilization was also sig-
nificantly higher in patients with DM (10.4% vs. 7.3% in 
non-DM; p = 0.015).
During the study period, 17 patients with DM (2.4%) 
and 21 without DM (1.4%) had a diagnosis of COVID-
19 by protein-chain reaction test for SARS-CoV-2 
(p = 0.157). Out of these patients, 11 (29.7%) died. 
Among patients with COVID-19 disease, 16 were dia-
betics, and 21 non diabetics, mortality being higher 
in diabetics (6/16; 37.5%) than in non diabetics (5/21; 
23.8%), but difference was  not statistically significant 
(p = 0.475).
Mortality in patients with and without DM among different 
subgroups
Mortality and cardiovascular mortality were higher in 
patients with DM regardless the main cardiovascular 
disease, although differences were statistically significant 
only for those patients with valvular heart disease (Fig. 3a 
and b).
Figure 4 shows the mortality and cardiovascular mor-
tality rates in patients with and without DM in the most 
frequent types of pending procedures. Mortality and car-
diovascular mortality rates were higher in patients pend-
ing on coronary diagnostic or therapeutic procedures, 
TAVI, and other diagnostic procedures, but differences 
reached statistical significance only for cardiovascular 
mortality in patients pending on TAVI. In patients pend-
ing on LAAC, mortality was higher in non-DM but dif-
ferences were not statistically different.
Fig. 2 Independent risk factors for mortality (a) and cardiovascular mortality (b)
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Tables  2 and 3 show the overall and cardiovascular 
mortality in patients with and without DM in different 
patient subgroups accordingly to clinical characteristics. 
No significant interaction was found between DM and 
other clinical variables (Table 4).
Discussion
Among patients in whom an elective cardiac invasive 
procedure was cancelled or postponed, those with DM 
had a significantly higher mortality, mainly due to a 
higher cardiovascular mortality. Overall mortality was 
3 times higher and cardiovascular mortality 4.75 times 
higher in DM in comparison with patients without DM.
Patients with DM had a worse clinical profile, including 
more advanced age, and higher prevalence of additional 
cardiovascular risk factors, previous cardiovascular dis-
eases, and some co-morbidities, such as renal failure. 
However, DM was an independent predictor both for 
mortality and cardiovascular mortality, indicating that 
DM per se is a risk factor in this special population. The 
main practical implication of these findings is that elec-
tive invasive cardiac procedures should be prioritized in 
patients with DM. That is, during COVID-19 pandemic, 
invasive cardiac procedures should not be postponed in 
patients with DM. Even, this may be applicable not only 
during COVID-19 pandemic in particular [7], but also 
in other situations in which health care system cannot 
Fig. 3 Mortality (a) and cardiovascular mortality (b) rates in patients with and without DM accordingly to the main cardiovascular disease
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adequately attend all patients pending on invasive proce-
dures, and in waiting list management of interventional 
cardiology in general.
No significant interaction was found between DM and 
other clinical variables. This simplifies the indication of 
not cancelling ICP in patients with DM, because mortal-
ity and cardiovascular mortality was higher in patients 
with DM irrespectively on other clinical characteristics.
The worse outcome in patients with DM may have 
several reasons. First, DM is associated with an 
impaired systolic and diastolic left ventricular func-
tion in patients without significant coronary artery 
disease [13], and this could have a negative impact 
on the outcome of patients with heart failure or val-
vular heart disease. Second, DM patients have a pro-
coagulant state [14] that may increase the risk of 
thromboembolic events in patients pending on struc-
tural interventions. Third, the response to anti-throm-
botic agents is impaired in patients with DM [15], 
and this could have an impact on the risk of ischemic 
events in patients pending on coronary interventions. 
Fourth, coronary artery disease is more frequent and 
more severe in patients with DM and  severe valvular 
disease [16], and this could have a negative prognostic 
impact on clinical outcome. Finally, DM predisposes 
to infections [18], that  constitute an important cause 
Fig. 4 Mortality (a) and cardiovascular mortality (b) in patients with and without DM accordingly to the type of pending procedure
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of non-cardiovascular death in elderly cardiovascular 
patients [19, 20].
DM had a negative impact on mortality in all type 
of pending ICP. DM is associated with more severe 
coronary stenosis [17], and is a very well known risk 
factor for mortality in patients with CAD [11, 12].
Among patients with aortic stenosis, those with DM 
have a higher mortality rate [21]. This may be partly 
Table 2 Mortality in patients with and without DM in different patients subgroups
PC Percutaneous coronary intervention. CABG Coronary artery bypass grafting, NYHA New York Heart Association, CCS Cardiology Canadian Society
Factor present
Yes No
DM Non‑DM P value DM Non‑DM P value
Age > 80 (%) 7.5 3.8 0.071 1.5 0.3 0.006
Female gender (%) 5.0 1.2 0.001 2.0 0.9 0.098
Hypertension (%) 3.3 1.1 0.003 0.0 0.7 0.362
Hypercholesterolemia (%) 3.3 1.2 0.012 1.5 0.7 0.378
Smoking (%) 1.0 0.2 0.262 3.4 1.2 0.004
Chronic renal failure (%) 9.9 2.8 0.036 2.0 0.9 0.044
Peripheral artery disease (%) 3.1 3.1 1.000 3.0 0.8  < 0.001
Previous CAD (%) 2.4 1.8 0.537 3.0 0.7 0.001
Previous infarction (%) 2.4 0.6 0.314 3.1 1.1 0.002
Previous PCI (%) 2.4 0.4 0.165 3.2 1.1 0.003
Previous CABG (%) 0.0 6.3 0.242 3.2 0.9  < 0.001
Previous valve replacement (%) 4.3 1.5 0.444 2.6 0.8 0.002
Left ventricular dysfunction (%) 1.6 0.7 0.370 3.2 1.0 0.001
NYHA > 2 (%) 7.1 2.5 0.061 2.1 0.7 0.014
CCS > 2 (%) 4.8 3.9 1.000 2.7 0.7 0.001
Table 3 Cardiovascular mortality in patients with and without DM in different patients subgroups
PCI Percutaneous coronary intervention, CABG Coronary artery bypass grafting, NYHA New York Heart Association, CCS Cardiology Canadian Society
Factor present
Yes No
DM Non‑DM P value DM Non‑DM P value
Age > 80 (%) 4.6 1.9 0.093 1.0 0.0 0.003
Female gender (%) 4.1 0.5 0.001 0.7 0.3 0.409
Hypertension (%) 2.3 0.5 0.002 0.0 0.2 1.000
Hypercholesterolemia (%) 2.0 0.6 0.023 1.5 0.1 0.032
Smoking (%) 0.5 0.0 0.335 2.3 0.5 0.002
Chronic renal failure (%) 7.7 1.9 0.083 1.0 0.3 0.079
Peripheral artery disease (%) 0.0 0.0 1.000 2.2 0.5  < 0.001
Previous CAD (%) 1.4 0.5 0.244 2.3 0.4 0.002
Previous infarction (%) 0.8 0.6 1.000 2.1 0.4  < 0.001
Previous PCI (%) 1.8 0.4 0.312 1.9 0.4 0.004
Previous CABG (%) 0.0 2.1 1.000 2.0 0.4  < 0.001
Previous valve replacement (%) 4.3 0.0 0.253 1.7 0.4 0.002
Left ventricular dysfunction (%) 1.1 0.7 0.635 2.2 0.4 0.001
NYHA > 2 (%) 5.1 1.2 0.049 1.6 0.2 0.004
CCS > 2 (%) 3.2 2.9 1.000 1.8 0.2  < 0.001
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explained by the higher frequency of some co-morbidi-
ties (e.g. renal insufficiency) and CAD [16], but DM also 
might have a direct effect on prognosis of these patients. 
Among patients with aortic stenosis, those with DM have 
a more impaired myocardial function and more severe 
hypertrophy [22]. In patients with aortic valve sclerosis, 
insulin resistance is a powerful independent predictor of 
subclinical left ventricular dysfunction regardless of con-
comitant visceral obesity and left ventricular hypertrophy 
[23]. Additionally, DM impairs coronary microvascu-
lar function in asymptomatic patients with severe aortic 
and non-obstructed coronary arteries [24]. Besides these 
potential explanations, cardiac mortality  rate was unex-
pectedly high in DM patients awaiting a valvular proce-
dure during  a relatively short follow-up (45  days), and 
this novel finding warrants further research.
Other procedures apart from coronary and valvular 
interventions had also higher mortality in patients with 
DM. DM is a risk factor for mortality in patients on atrial 
fibrillation [25], and thus it is not surprising that among 
patients  pending on LAAC, mortality was higher in 
diabetics.
Study limitations
This study has several limitations. First, the main goal 
of this study was to evaluate the short-term conse-
quences of delaying or postponing invasive cardiac 
procedures. Because of that, clinical follow-up was 
restricted to only 45  days. Second, metabolic control, 
treatment of diabetes and type of diabetes were not col-
lected, and therefore the potential influence of these 
factors could not be  evaluated. Finally, some patients 
underwent an emergent procedure due to clinical insta-
bilization. As this occurred more frequently in patients 
with DM, the influence of DM on mortality in our pop-
ulation even may have been underestimated.
Conclusion
Among patients in whom an elective invasive cardiac 
procedure is cancelled or postponed, those with DM 
have an especial worse clinical outcome, with higher 
mortality and cardiovascular mortality rates  at short-
term, irrespective on other clinical conditions. Elective 
invasive cardiac procedures should be prioritized in 
patients with diabetes.
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Age > 80 (%) 0.192 0.990
Female gender (%) 0.353 0176
Hypertension (%) 0.996 0.996
Hypercholesterolemia (%) 0.774 0.375
Smoking (%) 0.799 0.994
Chronic renal failure (%) 0.499 0.790
Peripheral artery disease (%) 0.128 1.000
Previous CAD (%) 0.102 0.478
Previous infarction (%) 0.774 0.361
Previous PCI (%) 0.550 0.950
Previous CABG (%)
 Previous valve replacement (%) 0.976 0.997
Left ventricular dysfunction (%)
 NYHA > 2 (%) 0.953 0.561
 CCS > 2 (%) 0.212 0.066
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